DE10218476A1 - Medicaments, cosmetics and dermatological compositions for a wide variety of skin treatments contain lignans or their glycosides - Google Patents

Abstract

Cosmetic and/or dermatological compositions contain lignans (or their glycosides) in addition to conventional ingredients.

Description

The present invention relates to cosmetic and / or dermatological preparations containing one or more lignans and / or their glycosides, in addition, if appropriate further cosmetic and / or dermatological active ingredients, auxiliaries and additives, and their use.

The skin is the largest organ in humans. It fulfills a variety of functions (e.g. heat regulation, sense organ for sensation of touch and warmth, barrier function, Protection against dehydration).

• - Oberhaut (Epidermis)
• - Lederhaut (Cutis, Corium, Dermis)
• - Unterhaut (Subcutis)

The skin can be divided into three histologically distinguishable layers:

• - epidermis
• - leather skin (cutis, corium, dermis)
• - subcutis

The outermost layer is the epidermis. As a boundary layer it forms the actual protective cover against the environment. With about a tenth of the total thickness it is also the thinnest layer of the skin.

The epidermis is a stratified tissue in which the outer layer, the horny layer (Stratum corneum), which is the important part for the barrier function. It will be in Worn out contact with the environment and is therefore in a constant Renewal process, whereby fine scales are continuously released to the outside cornified cell and lipid material is reproduced from the inside.

Under the epidermis is the dermis, also known as the corium or dermis becomes. The main function of this mesodermal connective tissue is to care for it the epidermis. It is made up of elastic, collagen and reticular fibers has a large number of plasma and mast cells.

The subcutis (subcutis) consists of loose connective tissue with more or less numerous stored fat cells. The thickness of the subcutaneous tissue depends first Line on nutrition, especially overeating. But also the genetic one Assessment plays a not insignificant role.

The subcutaneous tissue serves as heat protection, as mechanical padding and as Storage for nutrients and water. The training of the Fat pads in the lower layers of the skin are promoted. So can wearing mini skirts at low outside temperatures, an unpleasant thickening of the thighs gradually cause (so-called cellulitis).

• a) Trockenheit, Rauhigkeit und Ausbildung von Trockenheitsfältchen,
• b) Juckreiz und
• c) verminderte Rückfettung durch Talgdrüsen (z. B. nach Waschen).

The chronological skin aging is e.g. B. caused by endogenous, genetically determined factors. In the epidermis and dermis it occurs due to aging e.g. B. the following structural damage and malfunctions, which may also fall under the term "senile xerosis":

• a) dryness, roughness and formation of dry wrinkles,
• b) itching and
• c) Reduced regreasing by sebum glands (e.g. after washing).

• a) Sichtbare Gefäßerweiterungen (Teleangiektasien, Cuperosis);
• b) Schlaffheit und Ausbildung von Falten;
• c) lokale Hyper-, Hypo- und Fehlpigmentierungen (z. B. Altersflecken) und
• d) vergrößerte Anfälligkeit gegenüber mechanischem Stress (z. B. Rissigkeit).

Exogenous factors, such as UV light and chemical pollutants, can be cumulatively effective and e.g. B. accelerate or complement the endogenous aging processes. In the epidermis and dermis, it occurs in particular due to exogenous factors such. B. the following structural damage and functional disorders in the skin, which go beyond the extent and quality of the damage with chronological aging:

• a) Visible vasodilation (telangiectasia, cuperosis);
• b) flaccidity and wrinkling;
• c) local hyper, hypo and incorrect pigmentations (e.g. age spots) and
• d) increased susceptibility to mechanical stress (e.g. cracking).

Products for the care of sagging, especially aged skin are known per se. she contain z. B. retinoids (vitamin A acid and / or their derivatives) or vitamin A and / or its derivatives. However, their effect on structural damage is limited in scope. In addition, there are significant ones in product development Difficulty getting the active ingredients to a sufficient degree against oxidative decay stabilize. The use of products containing vitamin A acid also requires often severe erythematous skin irritation. Retinoids are therefore only minor Concentrations can be used.

Body awareness has been evident in the past few years gone up. In addition to cleaning and care applications, there are also increasing numbers Measures taken to improve body silhouette. Cellulitis - a far widespread phenomenon - occupies a central position. The visible picture of the Cellulitis is due to an increase in fat deposits in the subcutis (Subcutaneous fat tissue), a weak connective tissue as well as a reduction of the Flow conditions in the blood and lymph channels and low edema formation. It mostly occurs in the hip, thigh and gluteal region and is popularly called Inscribed "orange peel" and "mattress phenomenon". The cause is one in part Plant-related weakening of the connective tissue with the simultaneous appearance of enlarged fat cell chambers due to obesity, unbalanced nutrition, Lack of exercise. The emergence of cellulite can also be due to increased permeability of the hair vessel walls, which prevent the penetration of water into the Connective tissue allowed. Also a local excess of estrogens (or lack of Testosterone) can help produce cellulite almost exclusively in women to lead.

Cellulitis can be treated with soy extracts, as described in the writings of Schmidt and Wieland are disclosed (EP 0907351 B1, WO 97136570, US 6071526, US 5945109, US 5948808). The content of this prior art proves to be disadvantageous Isoflavonoids, which are contained in the soy extracts, as some compounds in this class have genotoxic potential (Pool-Zobel et al., Carcinogenesis, 21: 1247-1252 (2000); Kulling et al., Food and Chemical Toxicology, 35, 605-613 (1997); Morris et al., Mutation Research, 405, 41-56 (1998); by Rijn et al., Clinical Cancer Research, 3: 1775-1779 (1997); Gafter et al., The Journal of Laboratory and Clinical Medicine, 130, 33-41 (1997); Kaufmann et al., Prog. Soc. Exp. Biol. Med. 217, 327-334 (1998); Boos et al., Toxicology Letters, 116, 7-16 (2000).

It was therefore the object of the present invention to address the deficits in the prior art Eliminate technology and effective and compatible preparations are available places that can bring about a beneficial tightening of sagging skin. In addition to the Prophylaxis and reduction in the appearance of aging skin, should Preparations according to the invention in particular the treatment and prophylaxis of the Serve cellulitis.

The task is surprisingly solved by cosmetic and / or dermatological Preparations containing one or more lignans and / or their glycosides, in addition optionally further cosmetic and / or dermatological active ingredients, auxiliaries and Additives.

Lignans are dimers of phenylpropane derivatives that are linked to each other via the C-2 atom of the propane chain (2,2'-linkage). These are mostly colorless, crystalline, difficultly volatile compounds without smell and striking taste. As compounds of the plant secondary metabolism, they probably arise through radical-oxidative coupling of two phenylpropane derivatives and have the following basic structure:

• - Dibenzylbutane (z. B. Guajaretsäure, meso-Nordihydroguajaretsäure, Secoisolariciresinoldiglycosid, Enterodiol)
• - Dibenzylbutyrolactone (sog. Lignanolide wie Mataresinol, Enterolacton)
• - Tetrahydrofuranlignane (z. B. Sesamin, Cubebin, Pinoresinol).

In addition to the C-2-C-2 'bond, the base bodies can be linked by various further CC and COC bonds, which means that lignans can be divided into

• - Dibenzylbutanes (e.g. guajaretic acid, meso-nordihydroguajaretic acid, secoisolariciresinol diglycoside, enterodiol)
• - Dibenzylbutyrolactone (so-called lignanolides such as mataresinol, enterolactone)
• - tetrahydrofuran lignans (e.g. sesamin, cubebin, pinoresinol).

All of these classes of compounds can be used advantageously according to the invention.

According to the invention, the lignans secoisolariciresinol, matairesinol and its glycosides, sesamin, pinoresinol, cubebin, enterodiol, which have the following structures, are particularly preferred:

Of these compounds, both enantiomers are individual and in any Mixing ratios (e.g. as a racemate) can advantageously be used according to the invention.

Lignans are classified as phytoestrogens that are weak or estrogenic can have an anti-estrogenic effect (Kurzer et al., Ann. Rev. Nutr., 17, 353 (1997); Adlercreutz et al., J. Steroid Biochem., 27, 1135 (1987); Adlercreutz et al., Ann. Med., 29, 95 (1997); Chernick et al., J. Lip. Res., 27 (3), 286-294 (1986); Wang et al., J. Steroid Biochem. Mol. Bio, 50 (3-4), 205-212 (1994).

The writings of Schmidt and Wieland (EP 0907351 B1, WO 97/36570, US 6071526, US 5945109, US 5948808) estrogen-inhibiting active ingredients, inter alia based on aromatase inhibitors for the treatment of disturbed subcutaneous Connective tissue and especially cellulite revealed. However, these writings could not show the way to the present invention, since the disclosed preparations are not the Serve prophylaxis. Because the estrogenic or anti-estrogenic effect of lignans only is relatively weak, the extraordinarily high effectiveness was at the same time surprisingly good tolerance of lignan preparations just as unpredictable as the fact that there are preparations containing lignan can be formulated particularly easily and conveniently.

WO 01/08651 also describes topical compositions, which among others also Lignans may contain as a phenolic component, but refer to such Preparations not for the treatment and prophylaxis of cellulite. As imperative These compositions contain components for achieving a therapeutic effect unsaturated fatty acids and their derivatives (so-called petroselinic acids). However, these have the disadvantage of not being particularly durable. As in the Römpp chemical Lexicon (ed. J. Falbe, M. Regnitz, Georg Thieme Verlag, Stuttgart, 9th ed.) Under the Keyword rancidity, unsaturated fatty acids and their tend Derivatives to a lipooxygenase-catalyzed and also autooxidative decomposition, the leads to malodorous aldehydic degradation products. Last but not least, stayed in the WO 01/08651 the extraordinarily positive effect of glycosylated lignan derivatives unconsidered. Therefore, this document was unable to find the way to the present one To point invention.

It is advantageous according to the invention if in the cosmetic and / or dermatological preparations the lignans in a concentration of 0.001 to 15 % By weight, in particular from 0.01 to 5% by weight and very particularly preferably in a concentration of 0.1 to 2% by weight, based on the total weight of the Preparation can be used.

The lignans according to the invention can be used without problems in the usual cosmetic and / or dermatological preparations, such as sunscreen preparations, but also others Preparations, for example, incorporate pharmaceutical preparations.

Cosmetic and / or dermatological preparations usually contain one A large number of auxiliaries and active ingredients, which are also present in the preparations according to the invention can be used advantageously.

According to the invention, in the preparations containing the lignans, the usual antioxidants are used.

The antioxidants are advantageously selected from the group consisting of amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D, L-carnosine, D- Carnosine, L-carnosine and their derivatives (e.g. anserine), carotenoids, carotenes (e.g. α-carotene, β-carotene, lycopene) and their derivatives, aurothioglucose, propylthiouracil and other thiols (e.g. thioredoxin , Glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, γ-linoleyl, cholesteryl and Glyceryl esters) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as (metal) chelators (e.g. α-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin) , α-hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and derivatives thereof, unsaturated fatty acids and their derivatives (eg. B. γ-linolenic acid, linoleic acid, oleic acid), folic acid and its derivatives, alanine diacetic acid, flavonoids, polyphenols, catechins, vitamin C and derivatives (e.g. ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g. Vitamin E acetate), and coniferyl benzoate of benzoic resin, rutinic acid and its derivatives, ferulic acid and its derivatives, butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguajak resin acid, nordihydroguajaretic acid, trihydroxybutyrophenone, uric acid and its derivatives, zinc and its derivatives (zinose and its derivatives ZnO, ZnSO ₄ ) selenium and its derivatives (e.g. selenium methionine), stilbene and its derivatives (e.g. stilbene oxide, trans-stilbene oxide) and the derivatives suitable according to the invention (salts, esters, ethers, sugars, nucleotides, nucleosides , Peptides and lipids) of these active ingredients.

The amount of antioxidants (one or more compounds) in the preparations is preferably 0.001 to 10% by weight, particularly preferably 0.025-2.0% by weight, in particular 0.05-1.0% by weight, based on the total weight of the preparation.

If vitamin A or vitamin A derivatives, or carotenes or their derivatives, the or the antioxidants are advantageous, their respective concentrations from the Range from 0.001 to 10 wt .-%, based on the total weight of the formulation choose.

If vitamin E and / or its derivatives are the antioxidant (s) advantageous, the respective concentrations of which range from 0.001 to 10% by weight, based on the total weight of the formulation.

Further advantageous active ingredients in the sense of the present invention are natural Active ingredients and / or their derivatives, such as. B. alpha-lipoic acid, phytoene, D-biotin, coenzyme Q10, alpha-glucosylrutin, carnitine, carnosine, natural and / or synthetic Isoflavonoids, creatine, taurine and / or β-alanine.

Recipes according to the invention, which, for. B. known anti-wrinkle agents such Flavone glycosides (especially α-glycosylrutin), coenzyme Q10, vitamin E and / or derivatives and the like are particularly suitable for prophylaxis and Treatment of cosmetic or dermatological skin changes, such as z. B. at the Skin aging (such as dryness, roughness and formation of Wrinkles due to dryness, itching, reduced re-greasing (e.g. after washing), visible vasodilation (telangiectasias, cuperosis), flaccidity and training of wrinkles and fine lines, local hyper-, hypo- and incorrect pigmentations (e.g. Age spots), increased susceptibility to mechanical stress (e.g. cracking) and like). They are also advantageous against the appearance of the dry or rough skin.

Prophylaxis or cosmetic or dermatological treatment with the Lignans used according to the invention or with the cosmetic or topical ones dermatological preparations with an effective content of the invention Lignans used is carried out in the usual way, in such a way that the Lignans used according to the invention or the cosmetic or topical dermatological Preparations with an effective content of lignans used according to the invention is applied to the affected skin.

The preparations within the meaning of the present invention can preferably be in addition to a or one or more oil phases additionally contain one or more water phases and for example in the form of W / O, O / W, W / O / W or O / W / O emulsions. Such Formulations can preferably also be a microemulsion (e.g. a PIT Emulsion), a solid emulsions (i.e. an emulsion which is caused by solids is stabilized, e.g. B. a Pickering emulsion), a sprayable emulsion or a Be hydrodispersion. Furthermore, the preparations within the meaning of the present Invention also be almost water-free (water content below 5% by weight based on the total weight of the preparation). According to the invention, they are advantageous Preparations according to the invention also in the form of lipodispersions, gels, solid Pens or aerosols.

Preparations within the meaning of the present invention can, for. B. in the form of a cream, a lotion, a cosmetic milk, a mousse cream from an aerosol container available.

It is also possible and advantageous in the sense of the present invention that Lignans according to the invention in aqueous systems or surfactant preparations for cleaning the Insert skin.

It is of course known to those skilled in the art that sophisticated cosmetic Compositions are usually not conceivable without the usual auxiliaries and additives. The Cosmetic and / or dermatological preparations according to the invention can Contain cosmetic auxiliaries, as is usually the case in such preparations be used, e.g. B. emulsifiers, preservatives, preservation aids, Bactericides, perfumes, UV light protection filters, skin bleaching agents, self-tanners, Repellents, anti-foaming substances, dyes, pigments, the have a coloring effect, thickeners, moisturizing and / or moisturizing Substances, fillers that improve the feeling on the skin, fats, oils, waxes or others usual components of a cosmetic or dermatological formulation such as Alcohols, polyols, polymers, foam stabilizers, electrolytes, organic Solvents or silicone derivatives.

Medical topical compositions in the sense of the present invention usually contain one or more drugs in effective concentration. The For the sake of simplicity, it becomes a clear distinction between cosmetic and medical application and corresponding products to the legal Regulations of the Federal Republic of Germany referenced (e.g. cosmetics regulation, food and Medicinal Products Act).

Preparations according to the invention can also advantageously contain substances absorb the UV radiation in the UVB range, the total amount of Filter substances e.g. B. 0.1 wt .-% to 30 wt .-%, preferably 0.5 to 10 wt .-%, in particular Is 1.0 to 6.0 wt .-%, based on the total weight of the preparations to provide cosmetic preparations that cover the hair or skin protect the entire range of ultraviolet radiation. You can also use it as a Use sunscreen for your hair.

• - 3-Benzylidencampher-Derivate, vorzugsweise 3-(4-Methylbenzyliden)campher, 3- Benzylidencampher;
• - 4-Aminobenzoesäure-Derivate, vorzugsweise 4-(Dimethylamino)-benzoesäure(2- ethylhexyl)ester, 4-(Dimethylamino)benzoesäureamylester;
• - Ester der Zimtsäure, vorzugsweise 4-Methoxyzimtsäure(2-ethylhexyl)ester, 4-Methoxyzimtsäureisopentylester;
• - Ester der Salicylsäure, vorzugsweise Salicylsäure(2-ethylhexyl)ester, Salicylsäure(4-isopropylbenzyl)ester, Salicylsäurehomomenthylester,
• - Derivate des Benzophenons, vorzugsweise 2-Hydroxy-4-methoxybenzophenon, 2- Hydroxy-4-methoxy-4'-methylbenzophenon, 2,2'-Dihydroxy-4-methoxybenzophenon;
• - Ester der Benzalmalonsäure, vorzugsweise 4-Methoxybenzalmalonsäuredi(2-ethylhexyl)ester,
• - 2,4,6-Trianilino-(p-carbo-2'-ethyl-1'-hexyloxy)-1,3,5-triazin.

If the preparations according to the invention contain UVB film substances, they can be oil-soluble or water-soluble. Oil-soluble UVB filters advantageous according to the invention are e.g. B .:

• - 3-benzylidene camphor derivatives, preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
• - 4-aminobenzoic acid derivatives, preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
• - Esters of cinnamic acid, preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
• Esters of salicylic acid, preferably salicylic acid (2-ethylhexyl) ester, salicylic acid (4-isopropylbenzyl) ester, salicylic acid homomethyl ester,
• - Derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone;
• Esters of benzalmalonic acid, preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester,
• - 2,4,6-trianilino- (p-carbo-2'-ethyl-1'-hexyloxy) -1,3,5-triazine.

• - Salze der 2-Phenylbenzimidazol-5-sulfonsäure wie ihr Natrium-, Kalium- oder ihr Triethanolammonium-Salz, sowie die Sulfonsäure selbst;
• - Sulfonsäure-Derivate von Benzophenonen, vorzugsweise 2-Hydroxy-4-methoxybenzophenon-5-sulfonsäure und ihre Salze;
• - Sulfonsäure-Derivate des 3-Benzylidencamphers, wie z. B. 4-(2-Oxo-3-bornylidenmethyl)benzolsulfonsäure, 2-Methyl-5-(2-oxo-3-bornylidenmethyl)sulfonsäure und ihre Salze sowie das 1,4-di(2-oxo-10-Sulfo-3-bornylidenmethyl)-Benzol und dessen Salze (die entsprechenden 10-Sulfato-verbindungen, beispielsweise das entsprechende Natrium-, Kalium- oder Triethanolammoniurn-Salz), auch als Benzol-1,4- di(2-oxo-3-bornylidenmethyl-10-Sulfonsäure bezeichnet

Advantageous water-soluble UVB filters are e.g. B .:

• - Salts of 2-phenylbenzimidazole-5-sulfonic acid such as its sodium, potassium or triethanolammonium salt, and the sulfonic acid itself;
• - Sulfonic acid derivatives of benzophenones, preferably 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its salts;
• - Sulfonic acid derivatives of 3-benzylidene camphor, such as. B. 4- (2-oxo-3-bornylidenemethyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bornylidenemethyl) sulfonic acid and its salts and 1,4-di (2-oxo-10-sulfo- 3-bornylidene methyl) -benzene and its salts (the corresponding 10-sulfato compounds, for example the corresponding sodium, potassium or triethanolammonium salt), also as benzene-1,4-di (2-oxo-3-bornylidene methyl) Designated 10-sulfonic acid

The list of UVB filters mentioned in combination with the invention Active ingredient combinations can, of course, not be limiting his.

It can also be advantageous to use UVA filters that are usually contained in cosmetic preparations. These substances are preferably derivatives of dibenzoylmethane, in particular 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1,3-dione and 1-phenyl-3- (4 '-isopropylphenyl) propane-1,3-dione.
Further advantageous UVA filters come from the group of triazines, for. B. 2,4-bis - {[4- (2-ethylhexyloxy) -2-hydroxy] phenyl} -6- (4-methoyphanyl) -1,3,5-triazine (trade name Tinosorb® S) and the group of triazoles, such as. B. the 2,2'-methylene-bis- [6-2H-benzotriazol-2yl] -4- (1,1,3,3-tetramethylbutyl) phenol) (trade name Tinosorb® M). An advantageous water-soluble UVA filter is the 2'-bis- (1,4-phenylene) -1H-benzimidazole-4,6-disulfonic acid sodium salt (trade name Neo Heliopan AP®).

The quantities used for the UVB combination can be used.

Cosmetic and / or dermatological preparations according to the invention advantageously also contain inorganic pigments based on metal oxides and / or other metal compounds which are sparingly soluble or insoluble in water, in particular the oxides of titanium (TiO ₂ ), zinc (ZnO), iron (e.g. Fe ₂ O ₃ ), zirconium (ZrO ₂ ), silicon (SiO ₂ ), manganese (e.g. MnO), aluminum (Al ₂ O ₃ ), cerium (e.g. Ce ₂ O ₃ ), mixed oxides of the corresponding metals and Mixtures of such oxides. Pigments based on TiO _{2 are} particularly preferred.

It is particularly advantageous for the purposes of the present invention, although not mandatory if the inorganic pigments are in hydrophobic form, i. that is, they are treated to be water-repellent on the surface. This surface treatment can be in it exist that the pigments with a thin hydrophobic layer.

Such a method consists, for example, in that the hydrophobic surface layer according to a direction

n TiO ₂ + m (RO) ₃ Si-R '→ n TiO ₂ (surface)

is produced. n and m are stoichiometric parameters to be used at will, R and R 'are the desired organic radicals. For example, hydrophobized pigments shown in analogy to DE-OS 3314742 are advantageous.

Advantageous TiO ₂ pigments are available, for example, under the trade names MT 100 T from TAYCA, M 160 from Kemira and T 805 from Degussa.

Preparations according to the invention can, especially if crystalline or microcrystalline Solids, for example inorganic micropigments in the inventive Preparations are to be incorporated, including anionic, nonionic and / or contain amphoteric surfactants. Surfactants are amphiphilic substances that are organic, non-polar Can dissolve substances in water.

• - anionische Tenside,
• - kationische Tenside,
• - amphotere Tenside und
• - nichtionische Tenside.

The hydrophilic parts of a surfactant molecule are mostly polar functional groups, for example -COO ^- , -OSO ₃ ^2- , -SO ₃ ^- , while the hydrophobic parts generally represent non-polar hydrocarbon radicals. Surfactants are generally classified according to the type and charge of the hydrophilic part of the molecule. There are four groups:

• - anionic surfactants,
• - cationic surfactants,
• - amphoteric surfactants and
• - nonionic surfactants.

Anionic surfactants generally have carboxylate, sulfate or sulfonate groups as functional groups. In aqueous solution they form negatively charged organic ions in an acidic or neutral environment. Cationic surfactants are characterized almost exclusively by the presence of a quaternary ammonium group. In aqueous solution, they form positively charged organic ions in an acidic or neutral environment. Amphoteric surfactants contain both anionic and cationic groups and accordingly behave in aqueous solution like anionic or cationic surfactants depending on the pH. They have a positive charge in a strongly acidic environment and a negative charge in an alkaline environment. In the neutral pH range, however, they are zwitterionic, as the following example should illustrate:
RNH ₂ ⁺ CH ₂ CH ₂ COOH X ^- (at pH = 2) X ^- = any anion, e.g. B. Cl ^-

RNH ₂ ⁺ CH ₂ CH ₂ COO ^- (at pH = 7)

RNHCH ₂ CH ₂ COO ^- B ⁺ (at pH = 12) B ⁺ = any cation, e.g. B. Na ⁺
Polyether chains are typical of non-ionic surfactants. Non-ionic surfactants do not form ions in an aqueous medium.

A. Anionic surfactants

• 1. Acylglutamate, beispielsweise Natriumacylglutamat, Di-TEA-palmitoylaspartat und Natrium Caprylic/Capric Glutamat,
• 2. Acylpeptide, beispielsweise Palmitoyl-hydrolysiertes Milchprotein, Natrium Cocoylhydrolysiertes Soja Protein und Natrium-/Kalium Cocoylhydrolysiertes Kollagen,
• 3. Sarcosinate, beispielsweise Myristoyl Sarcosin, TEA-lauroyl Sarcosinat, Natriumlauroyisarcosinat und Natriumcocoylsarkosinat,
• 4. Taurate, beispielsweise Natriumlauroyltaurat und Natriummethylcocoyltaurat,
• 5. AcyILactylate, lauroyllactylat, Caproyllactylat
• 6. Alaninate

Anionic surfactants to be used advantageously are acylamino acids (and their salts), such as

• 1. acylglutamates, for example sodium acylglutamate, di-TEA-palmitoylaspartate and sodium caprylic / capric glutamate,
• 2. acyl peptides, for example palmitoyl-hydrolyzed milk protein, sodium cocoyl-hydrolyzed soy protein and sodium / potassium cocoyl-hydrolyzed collagen,
• 3. sarcosinates, for example myristoyl sarcosin, TEA lauroyl sarcosinate, sodium lauroyis sarcosinate and sodium cocoyl sarcosinate,
• 4. taurates, for example sodium lauroyl taurate and sodium methyl cocoyl taurate,
• 5. AcyILactylate, lauroyl lactylate, caproyl lactylate
• 6. Alaninate

• 1. Carbonsäuren, beispielsweise Laurinsäure, Aluminiumstearat, Magnesiumalkanolat und Zinkundecylenat,
• 2. Ester-Carbonsäuren, beispielsweise Calciumstearoyllactylat, Laureth-6 Citrat und Natrium PEG-4 Lauramidcarboxylat,
• 3. Ether-Carbonsäuren, beispielsweise Natriumlaureth-13 Carboxylat und Natrium PEG-6 Cocamid Carboxylat,

Carboxylic acids and derivatives, such as

• 1. carboxylic acids, for example lauric acid, aluminum stearate, magnesium alkanolate and zinc undecylenate,
• 2. ester carboxylic acids, for example calcium stearoyl lactylate, laureth-6 citrate and sodium PEG-4 lauramide carboxylate,
• 3. ether carboxylic acids, for example sodium laureth-13 carboxylate and sodium PEG-6 cocamide carboxylate,

Phosphoric acid esters and salts, such as DEA-oleth-10-phosphate and Dilaureth-4 phosphate,

• 1. Acyl-isethionate, z. B. Natrium-/Ammoniumcocoyl-isethionat,
• 2. Alkylarylsulfonate,
• 3. Alkylsulfonate, beispielsweise Natriumcocosmonoglyceridsulfat, Natrium C_12-14 Olefin-sulfonat, Natriumlaurylsulfoacetat und Magnesium PEG-3 Cocamidsulfat,
• 4. Sulfosuccinate, beispielsweise Dioctylnatriumsulfosuccinat, Dinatriumlaurethsulfosuccinat, Dinatriumlaurylsulfosuccinat und Dinatriumundecylenamido MEA-Sulfosuccinat

Sulfonic acids and salts such as

• 1. acyl isethionates, e.g. B. sodium / ammonium cocoyl isethionate,
• 2. alkylarylsulfonates,
• 3. alkyl sulfonates, for example sodium cocosmonoglyceride sulfate, sodium C _12-14 olefin sulfonate, sodium lauryl sulfoacetate and magnesium PEG-3 cocamide sulfate,
• 4. Sulfosuccinates, for example dioctyl sodium sulfosuccinate, disodium laureth sulfosuccinate, disodium lauryl sulfosuccinate and disodium undecylenamido MEA sulfosuccinate

such as

• 1. Alkylethersulfat, beispielsweise Natrium-, Ammonium-, Magnesium-, MIPA-, TIPA- Laurethsulfat, Natriummyrethsulfat und Natrium C1213 Parethsulfat,
• 2. Alkylsulfate, beispielsweise Natrium-, Ammonium- uncf TEA- Laurylsulfat.

Sulfuric acid esters, such as

• 1. alkyl ether sulfate, for example sodium, ammonium, magnesium, MIPA, TIPA laureth sulfate, sodium myreth sulfate and sodium C1213 pareth sulfate,
• 2. Alkyl sulfates, for example sodium, ammonium and uncf TEA lauryl sulfate.

B. Cationic surfactants

• 1. Alkylamine,
• 2. Alkylimidazole,
• 3. Ethoxylierte Amine und
• 4. Quaternäre Tenside.
• 5. Esterquats

Cationic surfactants to be used advantageously

• 1. alkylamines,
• 2. alkylimidazoles,
• 3. Ethoxylated amines and
• 4. Quaternary surfactants.
• 5. Esterquats

Quaternary surfactants contain at least one N atom that has 4 alkyl or aryl groups is covalently linked. Regardless of the pH value, this leads to a positive charge. Alkyl betaine, alkyl amidopropyl betaine and alkyl amidopropyl hydroxysulfain are advantageous. The cationic surfactants used according to the invention can also be preferred are selected from the group of quaternary ammonium compounds, in particular Benzyltrialkylammoniumchloride or bromide, such as Benzyldimethylstearylammonium chloride, furthermore alkyltrialkylammonium salts, for example for example Cetyltrimethylammonium chloride or bromide, Alkyldimethylhydroxyethylammonium chlorides or bromides, dialkyldimethylammonium chlorides or bromides, Alkylamidethyltrimethylammonium ether sulfates, alkylpyridinium salts, for example lauryl or Cetylpyrimidinium chloride, imidazoline derivatives and compounds with a cationic character such as amine oxides, for example alkyldimethylamine oxides or Alkylaminoethyldimethylamine. Cetyltrimethylammonium salts are particularly advantageous.

C. Amphoteric surfactants

• 1. Acyl-/dialkylethylendiamin, beispielsweise Natriumacylamphoacetat, Dinatriumacylamphodipropionat, Dinatriumalkylamphodiacetat, Natriumacylamphohydroxypropylsulfonat, Dinatriumacylamphodiacetat und Natriumacylamphopropionat,
• 2. N-Alkylaminosäuren, beispielsweise Aminopropylalkylglutamid, Alkylaminopropionsäure, Natriumalkylimidodipropionat und Lauroamphocarboxyglycinat.

Amphoteric surfactants to be used advantageously

• 1. acyl- / dialkylethylenediamine, for example sodium acylamphoacetate, disodium acylamphodipropionate, disodium alkylamphodiacetate, sodium acylamphohydroxypropylsulfonate, disodium acylamphodiacetate and sodium acylamphopropionate,
• 2. N-alkylamino acids, for example aminopropylalkylglutamide, alkylaminopropionic acid, sodium alkylimidodipropionate and lauroamphocarboxyglycinate.

D. Non-ionic surfactants

• 1. Alkohole,
• 2. Alkanolamide, wie Cocamide MEA/DEA/MIPA,
• 3. Aminoxide, wie Cocoamidopropylaminoxid,
• 4. Ester, die durch Veresterung von Carbonsäuren mit Ethylenoxid, Glycerin, Sorbitan oder anderen Alkoholen entstehen,
• 5. Ether, beispielsweise ethoxylierte/propoxylierte Alkohole, ethoxylierte/propoxylierte Ester, ethoxylierte/propoxylierte Glycerinester, ethoxylierte/propoxylierte Cholesterine, ethoxylierte/propoxylierte Triglyceridester, ethoxyliertes propoxyliertes Lanolin, ethoxylierte/propoxylierte Polysiloxane, propoxylierte POE-Ether und Alkylpolyglycoside wie Laurylglucosid, Decylglycosid und Cocoglycosid.
• 6. Sucroseester, -Ether
• 7. Polyglycerinester, Diglycerinester, Monoglycerinester
• 8. Methylglucosester, Ester von Hydroxysäuren

Non-ionic surfactants to be used advantageously

• 1. alcohols,
• 2. alkanolamides, such as cocamides MEA / DEA / MIPA,
• 3. amine oxides, such as cocoamidopropylamine oxide,
• 4. esters which are formed by esterification of carboxylic acids with ethylene oxide, glycerol, sorbitan or other alcohols,
• 5. ethers, for example ethoxylated / propoxylated alcohols, ethoxylated / propoxylated esters, ethoxylated / propoxylated glycerol esters, ethoxylated / propoxylated cholesterols, ethoxylated / propoxylated triglyceride esters, ethoxylated propoxylated lanolin, ethoxylated / propoxylated polysiloxanes, propoxylated POE ethers and alkylpolyglycosides such as lauryl polyglycosides cocoglycoside.
• 6. sucrose esters, ether
• 7. Polyglycerol esters, diglycerol esters, monoglycerol esters
• 8. Methyl glucose esters, esters of hydroxy acids

It is also advantageous to use a combination of anionic and / or amphoteric surfactants with one or more nonionic surfactants.

The surface-active substance can be in a concentration of between 1 and 30% by weight. are present in the preparations according to the invention, based on the total weight of the preparations.

• - Mineralöle, Mineralwachse
• - Öle, wie Triglyceride der Caprin- oder der Caprylsäure, ferner natürliche Öle wie z. B. Rizinusöl;
• - Fette, Wachse und andere natürliche und synthetische Fettkörper, vorzugsweise Ester von Fettsäuren mit Alkoholen niedriger C-Zahl, z. B. mit Isopropanol, Propylenglykol oder Glycerin, oder Ester von Fettalkoholen mit Alkansäuren niedriger C- Zahl oder mit Fettsäuren;
• - Alkylbenzoate;
• - Silikonöle wie Dimethylpolysiloxane, Diethylpolysiloxane, Diphenylpolysiloxane sowie Mischformen daraus.

The lipid phase of the cosmetic and / or dermatological preparations according to the invention can advantageously be selected from the following group of substances:

• - mineral oils, mineral waxes
• - Oils, such as triglycerides of capric or caprylic acid, as well as natural oils such. B. castor oil;
• - Fats, waxes and other natural and synthetic fat bodies, preferably esters of fatty acids with alcohols of low C number, e.g. B. with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids;
• - alkyl benzoates;
• - Silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes and mixed forms thereof.

The oil phase of the preparation of the present invention is advantageously selected from the Group of esters from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols Chain length of 3 to 30 carbon atoms, from the group of esters from aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols a chain length of 3 to 30 carbon atoms. Such ester oils can then be advantageous are selected from the group of isopropyl myristate, isopropyl palmitate, isopropyl stearate, Isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, Isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2-hexyldecyl stearate, 2-octyldodecyl palmitate, oleyl oleate, olerlerucate, erucyl oleate, erucylerucate and synthetic, semi-synthetic and natural mixtures of such esters, e.g. B. Jojoba oil.

Furthermore, the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the Group of saturated or unsaturated, branched or unbranched alcohols, as well as the fatty acid triglycerides, especially the saturated and / or triglycerol esters unsaturated, branched and / or unbranched alkane carboxylic acids of a chain length from 8 to 24, especially 12-18 C atoms. The fatty acid triglycerides can for example advantageously selected from the group of synthetic, semi-synthetic and natural oils, e.g. B. olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, Almond oil, palm oil, coconut oil, palm kernel oil and the like.

Any mixtures of such oil and wax components are also advantageous in To use the sense of the present invention. It can also be advantageous if necessary be waxes, for example cetyl palmitate, as the sole lipid component of the oil phase use.

The oil phase is advantageously selected from the group consisting of 2-ethylhexyl isostearate, octyldodecanol, isotridecylisononanoate, isoeicosane, 2-ethylhexyl cocoate, C _12-15 alkyl benzoate, caprylic capric acid triglyceride, dicaprylyl ether, dicaprylyl carbonate.

Mixtures of C _12-15 alkyl benzoate and 2-ethylhexyl isostearate, mixtures of C _12-15 alkyl benzoate and isotridecyl isononanoate and mixtures of C _12-15 alkyl benzoate, 2-ethyl hexyl isostearate and isotridecyl isononanoate are particularly advantageous.

Of the hydrocarbons, paraffin oil, squalane and squalene are advantageous in the sense to use the present invention.

The oil phase can advantageously also have a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils. Such silicones or silicone oils can be present as monomers, which are generally characterized by structural elements, as follows:

Linear silicones with a plurality of siloxy units which can advantageously be used according to the invention are generally characterized by structural elements as follows:


wherein the silicon atoms can be substituted with the same or different alkyl radicals and / or aryl radicals, which are generally represented here by the radicals R ₁ -R ₄ (to say that the number of different radicals is not necessarily limited to up to 4). m can assume values of 2-200,000.

Cyclic silicones to be used advantageously according to the invention are generally characterized by structural elements as follows


wherein the silicon atoms can be substituted with the same or different alkyl radicals and / or aryl radicals, which are generally represented here by the radicals R ₁ -R ₄ (to say that the number of different radicals is not necessarily limited to up to 4). n can take values from 3/2 to 20. Broken values for n take into account that there may be odd numbers of siloxyl groups in the cycle.

Cyclomethicone (eg decamethylcyclopentasiloxane) is advantageous as according to the invention silicone oil to be used. But other silicone oils are also advantageous in To use the sense of the present invention, for example Undecamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane), cetyldimethicone, Behenoxydimethicone.

Mixtures of cyclomethicone and isotridecyl isononanoate and are also advantageous those made from cyclomethicone and 2-ethylhexyl isostearate.

However, it is also advantageous to use silicone oils of a constitution similar to that above to select designated compounds whose organic side chains derivatize, for example, are polyethoxylated and / or polypropoxylated. These include, for example Polysiloxane-polyalkyl-polyether copolymers such as the cetyl-dimethicone copolyol, the (cetyl- Dimethicone copolyol (and) polyglyceryl 4-isostearate (and) hexyl laurate).

Mixtures of cyclomethicone and are also particularly advantageous Isotridecyl isononanoate, from cyclomethicone and 2-ethylhexyl isostearate.

The aqueous phase of the preparations according to the invention optionally contains advantageous alcohols, diols or polyols of low C number, and their ethers, preferably Ethanol, isopropanol, propylene glycol, glycerin, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, Diethylene glycol monomethyl or monoethyl ether and analog products, also alcohols low C number, e.g. As ethanol, isopropanol, 1,2-propanediol, glycerin and in particular one or more thickeners, which one or which are advantageously chosen can from the group silicon dioxide, aluminum silicates.

Preparations according to the invention particularly advantageously contain one or more Hydrocolloids. These hydrocolloids can advantageously be selected from the group the gums, polysaccharides, cellulose derivatives, layered silicates, polyacrylates and / or other polymers.

Preparations according to the invention which are present as hydrogels contain one or several hydrocolloids. These hydrocolloids can advantageously be from the aforementioned group to get voted.

Gums include plant or tree sap that harden in the air and Forming resins or extracts from aquatic plants. From this group can be advantageous in Gum arabic, for example Carob flour, tragacanth, karaya, guar gum, pectin, gellan gum, carrageenan, Agar, Algine, Chondrus, Xanthan Gum.

Another advantage is the use of derivatized gums such. B. Hydroxypropyl guar (Jaguar® HP 8).

Among the polysaccharides and derivatives are e.g. B. hyaluronic acid, chitin and Chitosan, chondroitin sulfates, starch and starch derivatives.

Among the cellulose derivatives are e.g. B. methyl cellulose, carboxymethyl cellulose, Hydroxyethyl cellulose, hydroxypropyl methyl cellulose.

Layered silicates include naturally occurring and synthetic ones Clays such as B. montmorillonite, bentonite, hectorite, laponite, magnesium aluminum silicates like Veegum®. These can be used as such or in a modified form such as z. B. Stearylalkonium Hektorite.

Furthermore, silica gels can also advantageously be used.

Among the polyacrylates are e.g. B. Carbopol types from Goodrich (Carbopol 980, 981, 1382, 5984, 2984, ETD 2001, ETD 2020, ETD 2050, Ultrez 10 or Pemulen TR1 & TR2).

Among the polymers are e.g. B. polyacrylamides (Seppigel 305), Polyvinyl alcohols, PVP, PVP / VA copolymers, polyglycols.

Preparations according to the invention which are present as emulsions contain one or several emulsifiers. These emulsifiers can advantageously be chosen from the Group of nonionic, anionic, cationic or amphoteric emulsifiers.

• a) Partialfettsäureester und Fettsäureester mehrwertiger Alkohole und deren ethoxylierte Derivate (z. B. Glycerylmonostearate, Sorbitanstearate, Glycerylstearylcitrate, Sucrosestearate)
• b) ethoxylierte Fettalkohole und Fettsäuren
• c) ethoxilierte Fettamine, Fettsäureamide, Fettsäurealkanolamide
• d) Alkylphenolpolyglycolether (z. B. Triton X)
• e) Zuckerderivate (Ester und/oder Ether von Glucose, Saccharose und anderen Zuckern; z. B. Alkylpolyglycoside wie Polyglyceryl-3-Methylglucose-Distearat, Methylglucosesesquistearat)

Among the nonionic emulsifiers are

• a) Partial fatty acid esters and fatty acid esters of polyhydric alcohols and their ethoxylated derivatives (e.g. glyceryl monostearates, sorbitan stearates, glyceryl stearyl citrates, sucrose stearates)
• b) ethoxylated fatty alcohols and fatty acids
• c) ethoxylated fatty amines, fatty acid amides, fatty acid alkanolamides
• d) alkylphenol polyglycol ether (e.g. Triton X)
• e) Sugar derivatives (esters and / or ethers of glucose, sucrose and other sugars; e.g. alkyl polyglycosides such as polyglyceryl-3-methylglucose distearate, methylglucose sesquistearate)

• a) Seifen (z. B. Natriumstearat)
• b) Fettalkoholsulfate
• c) Mono-, Di- und Trialkylphosphosäureester und deren Ethoxylate

Among the anionic emulsifiers are

• a) soaps (e.g. sodium stearate)
• b) fatty alcohol sulfates
• c) mono-, di- and trialkylphosphonic acid esters and their ethoxylates

• a) quaternäre Ammoniumverbindungen mit einem langkettigen aliphatischen Rest z. B. Distearyldimonium Chloride

Among the cationic emulsifiers are

• a) quaternary ammonium compounds with a long-chain aliphatic radical z. B. Distearyldimonium Chloride

• a) Alkylamininoalkancarbonsäuren
• b) Betaine, Sulfobetaine
• c) Imidazolinderivate

Among the amphoteric emulsifiers are

• a) Alkylamininoalkane carboxylic acids
• b) betaines, sulfobetaines
• c) Imidazoline derivatives

There are also naturally occurring emulsifiers, including beeswax, Wool wax, lecithin and sterols belong to it.

• - der Fettalkoholethoxylate
• - der ethoxylierten Wollwachsalkohole,
• - der Polyethylenglycolether der allgemeinen Formel R-O-(-CH₂-CH₂-O-)_n-R',
• - der Fettsäureethoxylate der allgemeinen Formel R-COO-(-CH₂-CH₂-O-)_n-H,
• - der veretherten Fettsäureethoxylate der allgemeinen Formel R-COO-(-CH₂-CH₂-O-)_n-R',
• - der veresterten Fettsäureethoxylate der allgemeinen Formel R-COO-(-CH₂-CH₂-O-)_n-C(O)-R',
• - der Polyethylenglycolglycerinfettsäureester
• - der ethoxylierten Sorbitanester
• - der Cholesterinethoxylate
• - der ethoxylierten Triglyceride
• - der Alkylethercarbonsäuren der allgemeinen Formel R-O-(-CH₂-CH₂-O-)_nCH₂-COOH nd n eine Zahl von 5 bis 30 darstellen,
• - der Polyoxyethylensorbitolfettsäureester,
• - der Alkylethersulfate der allgemeinen Formel R-O-(-CH₂-CH₂-O-)_nSO₃-H
• - der Fettalkoholpropoxylate der allgemeinen Formel R-O-(-CH₂-CH(CH₃)-O-)_n-H,
• - der Polypropylenglycolether der allgemeinen FormeL R-O-(-CH₂CH(CH₃)-O-)_n-R',
• - der propoxylierten Wollwachsalkohole,
• - der veretherten Fettsäurepropoxylate R-COO-(-CH₂CH(CH₃)-O-)_n-R'
• - der veresterten Fettsäurepropoxylate der allgemeinen Formel R-COO-{-CH₂-CH(CH₃)-O-)_n-C(O)-R',
• - der Fettsäurepropoxylate der allgemeinen Formel R-COO-(-CH₂-CH(CH₃)-O-)_n-H,
• - der Polypropylenglycolglycerinfettsäureester
• - der propoxylierten Sorbitanester
• - der Cholesterinpropoxylate
• - der propoxylierten Triglyceride
• - der Alkylethercarbonsäuren der allgemeinen Formel R-O-(-CH₂CH(CH₃)O-)_n-CH₂COOH
• - der Alkylethersulfate bzw. die diesen Sulfaten zugrundeliegenden Säuren der allgemeinen Formel R-O-(-CH₂-CH(CH₃)-O-)_n-SO₃-H
• - der Fettalkoholethoxylate/propoxylate der allgemeinen Formel R-O-X_nY_m-R,
• - der Polypropylenglycolether der allgemeinen Formel R-O-X_nY_mR',
• - der veretherten Fettsäurepropoxylate der allgemeinen Formel R-COO-X_n-Y_m-R',
• - der Fettsäureethoxylate/propoxylate der allgemeinen Formel R-COO-X_nY_m-H,.

O / W emulsifiers can, for example, advantageously be selected from the group of polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated products, e.g. B .:

• - The fatty alcohol ethoxylates
• - the ethoxylated wool wax alcohols,
• the polyethylene glycol ether of the general formula RO - (- CH ₂ -CH ₂ -O-) _n -R ',
• the fatty acid ethoxylates of the general formula R-COO - (- CH ₂ -CH ₂ -O-) _n -H,
• the etherified fatty acid ethoxylates of the general formula R-COO - (- CH ₂ -CH ₂ -O-) _n -R ',
• the esterified fatty acid ethoxylates of the general formula R-COO - (- CH ₂ -CH ₂ -O-) _n -C (O) -R ',
• - The polyethylene glycol glycerol fatty acid ester
• - The ethoxylated sorbitan esters
• - the cholesterol ethoxylates
• - The ethoxylated triglycerides
• the alkyl ether carboxylic acids of the general formula RO - (- CH ₂ -CH ₂ -O-) _n CH ₂ -COOH and n represent a number from 5 to 30,
• - the polyoxyethylene sorbitol fatty acid ester,
• - The alkyl ether sulfates of the general formula RO - (- CH ₂ -CH ₂ -O-) _n SO ₃ -H
• the fatty alcohol propoxylates of the general formula RO - (- CH ₂ -CH (CH ₃ ) -O-) _n -H,
• the polypropylene glycol ether of the general formula RO - (- CH ₂ CH (CH ₃ ) -O-) _n -R ',
• - the propoxylated wool wax alcohols,
• - the etherified fatty acid propoxylates R-COO - (- CH ₂ CH (CH ₃ ) -O-) _n -R '
• the esterified fatty acid propoxylates of the general formula R-COO - {- CH ₂ -CH (CH ₃ ) -O-) _n -C (O) -R ',
• the fatty acid propoxylates of the general formula R-COO - (- CH ₂ -CH (CH ₃ ) -O-) _n -H,
• - the polypropylene glycol glycerol fatty acid ester
• - The propoxylated sorbitan esters
• - the cholesterol propoxylates
• - the propoxylated triglycerides
• - The alkyl ether carboxylic acids of the general formula RO - (- CH ₂ CH (CH ₃ ) O-) _n -CH ₂ COOH
• - The alkyl ether sulfates or the acids on which these sulfates are based, of the general formula RO - (- CH ₂ -CH (CH ₃ ) -O-) _n -SO ₃ -H
• the fatty alcohol ethoxylates / propoxylates of the general formula ROX _n Y _m -R,
• the polypropylene glycol ether of the general formula ROX _n Y _m R ',
• the etherified fatty acid propoxylates of the general formula R-COO-X _n -Y _m -R ',
• - The fatty acid ethoxylates / propoxylates of the general formula R-COO-X _n Y _m -H ,.

According to the invention, the polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated O / W emulsifiers chosen from the group of substances with HLB values of 11-18, especially advantageous with HLB values of 14.5-15.5, provided the O / W emulsifiers are saturated residues R and R 'have. If the O / W emulsifiers have unsaturated radicals R and / or R ', or if there are isoalkyl derivatives, the preferred HLB value of such emulsifiers can be are also lower or higher.

It is advantageous to use fatty alcohol ethoxylates from the group of ethoxylated Stearyl alcohols, cetyl alcohols, cetyl stearyl alcohols (cetearyl alcohols) to choose. In particular preferred are:

Polyethylene glycol (13) stearyl ether (steareth-13), polyethylene glycol (14) stearyl ether (Steareth-14), polyethylene glycol (15) stearyl ether (Steareth-15), Polyethylene glycol (16) stearyl ether (Steareth-16), polyethylene glycol (17) stearyl ether (Steareth-17), polyethylene glycol (18) stearyl ether (Steareth-18), polyethylene glycol (19) stearyl ether (Steareth-19), Polyethylene glycol (20) stearyl ether (Steareth-20),

Polyethylene glycol (12) isostearyl ether (isosteareth-12), Polyethylene glycol (13) isostearyl ether (isosteareth-13), polyethylene glycol (14) isostearyl ether (isosteareth-14), Polyethylene glycol (15) isostearyl ether (isosteareth-15), polyethylene glycol (16) isostearyl ether (Isosteareth-16), polyethylene glycol (17) isostearyl ether (isosteareth-17), polyethylene glycol- (18) isostearyl ether (isosteareth-18), polyethylene glycol (19) isostearyl ether (isosteareth-19- ), Polyethylene glycol (20) isostearyl ether (isosteareth-20),

Polyethylene glycol (13) cetyl ether (ceteth-13), polyethylene glycol (14) cetyl ether (ceteth-14), Polyethylene glycol (15) cetyl ether (ceteth-15), polyethylene glycol (16) cetyl ether (ceteth-16), Polyethylene glycol (17) cetyl ether (ceteth-17), polyethylene glycol (18) cetyl ether (ceteth-18), Polyethylene glycol (19) cetyl ether (ceteth-19), polyethylene glycol (20) cetyl ether (ceteth-20),

Polyethylene glycol (13) isocetyl ether (isoceteth-13), polyethylene glycol (14) isocetyl ether (Isoceteth-14), polyethylene glycol (15) isocetyl ether (isoceteth-15), Polyethylene glycol (16) isocetyl ether (isoceteth-16), polyethylene glycol (17) isocetyl ether (isoceteth-17), Polyethylene glycol (18) isocetyl ether (isoceteth-18), polyethylene glycol (19) isocetyl ether (isoceteth-19), Polyethylene glycol (20) isocetyl ether (isoceteth-20),

Polyethylene glycol (12) oleyl ether (Oleth-12), polyethylene glycol (13) oleyiether (Oleth-13), Polyethylene glycol (14) oleyl ether (Oleth-14), polyethylene glycol (15) oleyl ether (Oleth-15),

Polyethylene glycol (12) lauryl ether (Laureth-12), polyethylene glycol (12) isolauryl ether (Isolaureth-12).

Polyethylene glycol (13) cetyl stearyl ether (ceteareth-13), Polyethylene glycol (14) cetyl stearyl ether (ceteareth-14), polyethylene glycol (15) cetyl stearyl ether (ceteareth-15), Polyethylene glycol (16) cetyl stearyl ether (ceteareth-16), polyethylene glycol (17) cetyl stearyl ether (Ceteareth-17), polyethylene glycol (18) cetylstearyl ether (Ceteareth-18), polyethylene glycol (19) - cetylstearyl ether (ceteareth-19), polyethylene glycol (20) cetylstearyl ether (ceteareth-20),

It is also advantageous to choose the fatty acid ethoxylates from the following group:
Polyethylene glycol (20) stearate, polyethylene glycol (21) stearate, polyethylene glycol (22) stearate, polyethylene glycol (23) stearate, polyethylene glycol (24) stearate, polyethylene glycol (25) stearate,

Polyethylene glycol (12) isostearate, polyethylene glycol (13) isostearate, Polyethylene glycol (14) isostearate, polyethylene glycol (15) isostearate, polyethylene glycol (16) isostearate, Polyethylene glycol (17) isostearate, polyethylene glycol (18) isostearate, polyethylene glycol (19) isostearate, Polyethylene glycol (20) isostearate, polyethylene glycol (21) isostearate, Polyethylene glycol (22) isostearate, polyethylene glycol (23) isostearate, polyethylene glycol (24) isostearate, Polyethylene glycol (25) isostearate,

Polyethylene glycol (12) oleate, polyethylene glycol (13) oleate, polyethylene glycol (14) oleate, Polyethylene glycol (15) oleate, polyethylene glycol (16) oleate, polyethylene glycol (17) oleate, Polyethylene glycol (18) oleate, polyethylene glycol (19) oleate, polyethylene glycol (20) oleate

As an ethoxylated alkyl ether carboxylic acid or its salt, this can be advantageous Sodium laureth-11 carboxylate can be used.

Sodium laureth 1-4 sulfate can advantageously be used as alkyl ether sulfate.

As an ethoxylated cholesterol derivative can be advantageous Polyethylene glycol (30) cholesteryl ether can be used. Polyethylene glycol (25) soyasterol has also proven itself.

Polyethylene glycol (60) evening can advantageously be used as ethoxylated triglycerides Primrose Glycerides can be used (Evening Primrose = evening primrose).

Another advantage is the polyethylene glycol glycerol fatty acid ester from the group Polyethylene glycol (20) glyceryl laurate, polyethylene glycol (21) glyceryl laurate, polyethylene glycol (22) glyceryl laurate, polyethylene glycol (23) glyceryl laurate, Polyethylene glycol (6) glyceryl caprate / caprinate, polyethylene glycol (20) glyceryl oleate, Polyethylene glycol (20) glyceryl isostearate, polyethylene glycol (18) glyceryl oleate / cocoat to choose.

It is also cheap to use the sorbitan esters from the group Polyethylene glycol (20) sorbitan monolaurate, polyethylene glycol (20) sorbitan monostearate, Polyethylene glycol (20) sorbitan monoisostearate, polyethylene glycol (20) sorbitan monopalmitate, Polyethylene glycol (20) sorbitan monooleate to choose.

Advantageous W / O emulsifiers that can be used are: fatty alcohols with 8 to 30 Carbon atoms, monoglycerol esters saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12-18 C atoms, diglycerol esters saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12-18 C atoms, monoglycerol ethers of saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12-18 carbon atoms, diglycerol ether saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12-18 C- Atoms, propylene glycol esters saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12-18 C atoms and sorbitan esters saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12-18 C-atoms.

Particularly advantageous W / O emulsifiers are glyceryl monostearate, Glyceryl monoisostearate, glyceryl monomyristate, glyceryl monooleate, diglyceryl monostearate, Diglyceryl monoisostearate, propylene glycol monostearate, propylene glycol monoisostearate, Propylene glycol monocaprylate, propylene glycol monoiaurate, sorbitan monoisostearate, Sorbitan monolaurate, sorbitan monocaprylate, sorbitan monoisooleate, sucrose distearate, cetyl alcohol, Stearyl alcohol, arachidyl alcohol, behenyl alcohol, isobehenyl alcohol, selachyl alcohol, Chimyl alcohol, polyethylene glycol (2) stearyl ether (steareth-2), glyceryl monolaurate, Glyceryl monocaprinate, glyceryl monocaprylate.

The use of cosmetic and / or dermatological preparations for the treatment of the symptoms of aging skin.

In particular, the use of the cosmetic and / or dermatological preparations for the treatment of cellulite according to the invention.

Another use of cosmetic according to the invention and / or dermatological preparations is the treatment of lymphatic congestion and Edema.

Last but not least, the cosmetic and / or dermatological invention Preparations to tighten and smooth the skin, to strengthen the connective tissue of the Skin, to suppress the formation of adipose tissue and to reduce fat in the skin are advantageously used according to the invention.

The use of lignans and / or their glycosides is also according to the invention Manufacture of a medicament for the prophylaxis and treatment of the symptoms of Age skin, for the prophylaxis and treatment of cellulite for the prophylaxis and treatment of lymph congestion and edema formation, for tightening and smoothing the skin, for strengthening of the connective tissue of the skin and / or for prophylaxis and treatment vvn Fat deposits in the skin.

The following examples are intended to illustrate the present invention without restricting it. Unless otherwise stated, all quantities, proportions and percentages are based on the weight and the total amount or on the total weight of the preparations. 1. PIT emulsions



2. Examples of O / W cream



3. Examples of O / W cream

4. Examples of W / O emulsions



5. Examples of W / O emulsions

6. Examples of hydrodispersions



7th example (gel cream)

Example 8 (W / O cream)



Example 9 (W / O / W cream)

10. Example W / O pen



11. Example W / O pen

12. Sunscreen emulsion



13. Sunscreen emulsion

14. Sunscreen emulsion

Claims (9)

1. Cosmetic and / or dermatological preparations containing one or more Lignans and / or their glycosides, in addition to any other cosmetic ones and / or dermatological active ingredients, auxiliaries and additives. 2. Cosmetic and / or dermatological preparations according to claim 1, characterized characterized that as lignans Secoisolariciresinol, Matairesinol and / or its Glycosides, sesamin, pinoresinol, cubebin, enterodiol can be used. 3. Cosmetic and / or dermatological preparations according to one of claims 1 or 2, characterized in that the lignans in a concentration of 0.001 up to 15% by weight based on the total weight of the preparation become. 4. Use of lignans and / or their glycosides for the production of a Medicament and / or cosmetic and / or dermatological preparations for Prophylaxis and treatment of the symptoms of aging skin. 5. Use of lignans and / or their glycosides for the production of a Medicament and / or cosmetic and / or dermatological preparations for Prophylaxis and treatment of cellulite. 6. Use of lignans and / or their glycosides for the preparation of a Medicament and / or cosmetic and / or dermatological preparations for Prophylaxis and treatment of lymph congestion and edema formation. 7. Use of lignans and / or their glycosides for the preparation of a Medicament and / or cosmetic and / or dermatological preparations for Firming and smoothing the skin. 8. Use of lignans and / or their glycosides for the preparation of a Medicament and / or cosmetic and / or dermatological preparations for Strengthen the connective tissue of the skin. 9. Use of lignans and / or their glycosides for the preparation of a Medicament and / or cosmetic and / or dermatological preparations for Prophylaxis and treatment of fat deposits in the skin.